+

WO2000066088A1 - Composition pharmaceutique a liberation controlee contenant du metamizol - Google Patents

Composition pharmaceutique a liberation controlee contenant du metamizol Download PDF

Info

Publication number
WO2000066088A1
WO2000066088A1 PCT/EP2000/003885 EP0003885W WO0066088A1 WO 2000066088 A1 WO2000066088 A1 WO 2000066088A1 EP 0003885 W EP0003885 W EP 0003885W WO 0066088 A1 WO0066088 A1 WO 0066088A1
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
pharmaceutical composition
metamizole
cellulose
pharmaceutically acceptable
Prior art date
Application number
PCT/EP2000/003885
Other languages
German (de)
English (en)
Inventor
Thomas Strüngmann
Karin Klokkers
Brigitte Freudensprung
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Priority to AU45594/00A priority Critical patent/AU4559400A/en
Publication of WO2000066088A1 publication Critical patent/WO2000066088A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the invention relates to a controlled-release, solid, orally administered pharmaceutical composition which contains a therapeutically effective amount of metamizole and / or its pharmaceutically acceptable salts as active ingredients, embedded in a controlled-release matrix.
  • Metamizole N-methyl-N- (2,3-dimethyl-5-oxo-l-phenyl-3-pyrazolin-4-yl) aminomethanesulfonic acid, is an antipyretic analgesic.
  • the analgesic effect is achieved by damping the central pain perception as a result of activation of neurons in the pain-relieving system.
  • the lowering of the increased body temperature is mediated by the attack on the hypothalamic heat regulation center, as a result of which an increased heat release via the periphery occurs.
  • the absorption of metamizole is preceded by hydrolysis to 4-methylaminoantipyrine in the liver.
  • 4-Methylaminoantipyrin and the resulting 4-aminoantipyrine are the pharmacologically active metabolites of metamizole, while the other metabolites 4-acetylaminoantipyrine (main metabolite in urine) and 4-formylaminoantipyrine are considered to be much less pharmacologically active or inactive.
  • the dosage forms previously on the market are only quick-release. They are used to treat severe acute and chronic pain as well as fever.
  • the therapy with fast-releasing active substances tries to maintain a sustained therapeutically effective blood plasma level of the active substance by frequent and at the same time taking the active substance, large fluctuations in the blood plasma level occur due to the immediate absorption, the systemic excretion and the hepatic metabolism of the active substance. This can severely impair the effectiveness of the active ingredient.
  • a very high blood plasma level of the active ingredient is reached for a short time. The blood plasma level drops shortly after ingestion and a sufficient therapeutic effect can no longer be guaranteed.
  • metamizole is used not only for the treatment of acute but often also for chronic pain, an optimal and constant effect over a longer period of time cannot be guaranteed when taking the previously known rapid-release pharmaceutical compositions.
  • the object of the present invention is to provide a pharmaceutical composition containing metamizole and / or its pharmaceutically acceptable salts, which ensures a therapeutically effective, constant blood plasma level over a period of at least 8 hours.
  • a pharmaceutical composition containing metamizole and / or its pharmaceutically acceptable salts which has a solid consistency, is to be administered orally, releases the active substance in a matrix-controlled manner and over a period of at least 8 to 12 hours, optionally up to 24 hours ensures a therapeutically effective blood plasma level.
  • an optimal effectiveness against the pain can be achieved with minimal side effects.
  • patient compliance is improved by the reduced frequency of ingestion.
  • metamizole is very water-soluble, it was not to be expected that a matrix-controlled slow release formulation would guarantee a satisfactory, delayed release.
  • Particularly suitable pharmaceutically acceptable salts of metamizole are alkali metal salts, such as the potassium, sodium and lithium salts, in particular the metamizole sodium monohydrate, and the ammonium salt.
  • composition according to the invention contains an analgesically effective amount of metamizole and / or its pharmaceutically acceptable salts of 500-2500 mg per dosage unit.
  • metamizole sodium monohydrate per dosage unit 500-2000 mg, in particular 500 mg, 1000 mg and 1500 mg metamizole sodium monohydrate per dosage unit is preferred.
  • composition according to the invention can be in the form of granules, pellets, spheroids. These can either be filled into capsules or sachets or pressed into tablets or tabs. If necessary, the active ingredient and possible excipients can also be tabletted directly.
  • the tabs or sachets are dispersed in water before ingestion, i.e. after the addition of the tabs or sachet to water, the retarded particles are finely dispersed in the water and can be drunk by the patient, the retarding effect being retained and the ingestion is made easier for the patient since there are no difficulty swallowing.
  • the active ingredient metamizole and / or its pharmaceutically acceptable salts used in the composition according to the invention can be embedded in a matrix.
  • This matrix ensures the controlled release of metamizole and / or its pharmaceutically acceptable salts over a period of at least 8 to 12 hours and possibly up to 24 hours (matrix-controlled).
  • Hydrophilic or hydrophobic polymers e.g. Starch, polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose,
  • Hydroxymethyl cellulose poly (vinyl alcohols), alginates, polydextrose, carboxymethylene, hydrogenated hydroxyalkyl cellulose, hydroxypropyl methyl cellulose ether, polyvinyl chloride, Ethyl cellulose, methyl cellulose, carboxymethyl cellulose, cellulose acetates,
  • Cellulose acetate phthalates ethylene vinyl alcohol, alginic acid and / or their derivatives, acrylic acid and / or methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylate copolymers, cyanoethyl methacrylates, aminoalkyl methacrylate copolymers, poly (acrylic acid), poly (methacrylic acid), methacrylic acid alkyl polyamide methyl methacrylate), poly (methacrylic anhydride), methyl methacrylate,
  • Polymethacrylates poly (methyl methacrylate) copolymer, polyacrylamides,
  • Methylcellulose, polyvinylpyrrolidone and / or alginic acid and / or their salts and / or derivatives are preferably used as matrix formers in the composition according to the invention.
  • the composition according to the invention contains 1-90% (weight percent) of one or more of the hydrophilic or hydrophobic polymers as a matrix.
  • the preferred matrix form according to the invention can the active ingredient metamizole and / or its pharmaceutically acceptable salts in a gel-forming matrix from e.g.
  • Methyl cellulose hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose,
  • Hydroxypropylmethylcellulose, alginate and / or polyacrylic acid in particular
  • Methyl cellulose embedded, included.
  • the polymer hydrates and forms a gel-like
  • composition according to the invention contains 5-25% by weight, in particular 10-25
  • a further matrix form according to the invention can contain known water-soluble auxiliary substances which, like the active substance, are embedded in a framework formed from water-insoluble, indigestible auxiliary substances. By removing the soluble components, pores are created through which the active ingredient diffuses outwards.
  • Polymers such as polyvinyl chloride, polyethylene, polyamide, silicone, ethyl cellulose and methacrylic acrylate copolymers can be used as scaffolding substances.
  • the active ingredient Auxiliary mixture is pressed either directly or after wet granulation with organic solvents or binder solutions into tablets or tabs or filled in capsule or sachet in pellet form.
  • compositions which are common in the art, e.g. Diluents, lubricants, binders, granulation aids, colorants, flavors, detergents, buffers, non-stick agents and lubricants can also be contained in the controlled release matrix.
  • composition according to the invention embedded in a controlled-release matrix can also be film-coated with a known, pharmaceutically suitable, non-controlled-release coating agent, an aqueous film coating being preferred.
  • the release rate of the sustained release composition according to the invention is 5-50% (weight percent) metamizole and / or the corresponding pharmaceutically acceptable salts after one hour, 10-75% (weight percent)
  • the delayed-release composition according to the invention at least 70-95% (weight percent) of metamizole and / or the corresponding pharmaceutically acceptable salts is obtained after eight hours, and at least 77-97 after ten hours
  • Another embodiment of the invention can consist of an initial dose (ID) and a delayed release component.
  • the initial dose contains metamizole and / or its pharmaceutically acceptable salts as powder, granules and / or pellets, each in addition to optional adjuvants.
  • the metamizole and / or its pharmaceutically acceptable salts contained in the initial dose is released immediately after ingestion.
  • the therapeutically effective blood plasma level is reached very quickly by means of this initial dose, so that a therapeutic effect can be seen shortly after ingestion.
  • the delayed-release component contains metamizole and / or its pharmaceutically acceptable salts as granules and / or pellets, each in addition to optional auxiliaries. This delayed release component is responsible for maintaining the therapeutically effective blood plasma level for several hours.
  • the patient can thus be guaranteed a consistently high blood plasma level for several hours.
  • the granules or the pellets can contain retarding auxiliaries which form a controlled release matrix.
  • the matrix formers mentioned above can be used as suitable substances which form a controlled release matrix.
  • the above-mentioned information regarding the amount of retardant and active ingredient content also apply to the ID formulation.
  • the content of metamizole and / or its pharmaceutically acceptable salts can be 5-50% by weight of the total active substance content.
  • the ratio of active substance content in the initial dose to active substance content in the delayed-release component can be 1: 1 to 1: 5.
  • a ratio of 1: 1, 1: 2, 1: 3 or 1: 4 is preferred.
  • the composition according to the invention can be in the form of sachets, the sachet containing the initial dose and the retarding component, as described above.
  • the initial dose can be in the form of powder, granules and / or pellets.
  • the retarding component can be present as granules and / or pellets.
  • the sachet content is dissolved in water before ingestion so that the initial dose is in solution and the retarded particles are finely dispersed in the solution.
  • the preparation according to the invention can be in the form of tabs, the initial dose being pressed with the retarding component.
  • the initial dose can be pressed in the form of powder, granules and / or pellets.
  • the retarding component can be pressed in the form of granules and / or pellets.
  • the tabs are dissolved in water before ingestion so that the initial dose is in solution and the retarded particles are finely dispersed in the solution.
  • the preparation according to the invention can be in the form of a two-layer tablet.
  • the first layer represents the initial dose which is pressed from powder and optionally auxiliary substances, the granulate and / or pellets described above.
  • the second layer contains the delayed-release component described above, which is pressed from the corresponding granules and / or pellets.
  • the release rate of the sustained release composition according to the invention with the initial dose (ID formulation) in vitro is 15-30% (weight percent) metamizole and / or the corresponding pharmaceutically acceptable salts after 30 minutes, 30-60% (weight percent) metamizole and / or the corresponding pharmaceutically acceptable salts after three hours and more than 70% (weight percent) metamizole and / or the corresponding pharmaceutically acceptable salts after eight hours.
  • the pharmaceutical auxiliaries known in the prior art such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, retardants and / or antioxidants, and / or other known carriers and / or Thinners are used.
  • Metamizole sodium 1 H 2 O, methyl cellulose and lactose are mixed and passed through a sieve. This mixture is then moistened with a solution of PVP and water. Then it is granulated in a fluidized bed granulator. The granules are mixed with microcrystalline cellulose, magnesium stearate and Aerosil and compressed into tablets.
  • Metamizole sodium 1 H 2 O, methyl cellulose and lactose are mixed and passed through a sieve. This mixture is then moistened with a solution of PVP and water. Then it is granulated in a fluidized bed granulator. The granulate comes with microcrystalline cellulose, magnesium stearate and Aerosil mixed and compressed into tablets.
  • Metamizole sodium 1 H 2 O, methyl cellulose and lactose are mixed and passed through a sieve. This mixture is then moistened with a solution of PVP and water. Then it is granulated in a fluidized bed granulator. The granulate is mixed with magnesium stearate and Aerosil and filled into sachets.
  • Metamizole sodium 1 H 2 O, mannitol, lactose, hydroxyethyl cellulose and hydroxypropyl cellulose (15 g as a binder) are mixed dry.
  • the mixture is then moistened with water until a moist granulating compound is obtained.
  • the moistened mixture is then lightly dried in a Fluid Bed Dryer (FBD) at 60 ° C., granulated and sieved through a sieve with a mesh size of 12.
  • the granules are then completely dried in an FBD at 60 ° C., regranulated and sieved through a 1.25 mm sieve (mesh size 16).
  • Molten cetylstearyl alcohol is added to the warm metamizole sodium 1 H 2 O granules and mixed.
  • the mixture is cooled in an air stream, regranulated and sieved through a 1.25 mm sieve.
  • the remaining hydroxypropyl cellulose (10 g) is added to the mixture and mixed with the granules until the granules have a sufficiently thick coating of hydroxypropyl cellulose.
  • the granules are then pressed into tablets. If necessary, the tablets can still be coated with standard coatings.
  • Dioctyl sodium sulphosuccinate is dissolved in isopropanol.
  • Carboxymethyl cellulose is mixed with this solution until the mixture is homogeneous.
  • the mixture is then granulated and sieved through a 16 mesh screen.
  • the granules are dried in an air stream until all of the isopropanol has evaporated.
  • Metamizole sodium 1 H 2 O and lactose are added and mixed.
  • Magnesium stearate and talc are then added and mixed until a homogeneous mixture is obtained. Following is the mixture was regranulated and sieved through a 16 mesh screen.
  • the granules obtained are pressed into tablets or filled into sachets.
  • the amount per tablet or sachet of metamizole sodium 1 H 2 O is 1000 mg. 1000 pieces are made, each with a total weight of 1513mg.
  • Metamizole sodium 1 H 2 O and polyvinyl pyrrolidone (PVP) are mixed rapidly in an appropriate apparatus.
  • Eudragit is dissolved in acetone / isopropanol (50:50) (granulation fluid).
  • This granulation fluid is then slowly added during the mixing process of metamizole sodium 1 H 2 O and PVP until a moist granulation mass is formed.
  • the resulting granulate is then dried and sieved through a sieve with a mesh size of 12.
  • the cetostearyl alcohol melted at a temperature of 60-70 ° C is added to the still warm granulate and mixed. After cooling, the granules are sieved through a 1.7 mm sieve. Then the talc and magnesium stearate are added and mixed in.
  • the granules are either compressed into tablets or filled into sachets.
  • metamizole sodium 1 H 2 O 500 g is mixed with 40 g of ethyl cellulose and 25 g of polyvinylpyrrolidone. Then 140 g lactose and 203 g talc are added, moistened with a sufficient amount of alcohol and granulated and then dried. The granules obtained are either compressed into tablets or filled into capsules.
  • a dose unit produced in this way contains 500 mg of metamizole sodium 1 H 2 O.
  • Kollidon is dissolved in water and the green paint is dispersed in it. Metamizole sodium 1 H 2 O, lactose and metolose are placed in a fluidized bed granulator and granulated with the previously prepared solution. Magnesium stearate is added to the granules obtained and Aerosil added and passed through a 1.0 mm forced sieve and homogenized in the container mixer.
  • the entire ingredients of the initial dose are passed through a 0.8 mm forced sieve and homogenized in the container mixer.
  • the prolonged-release granules are compressed with the initial dose on a suitable rotary tablet machine to form two-layer tablets.
  • metamizole sodium 1 H 2 O ID sachet The following two components are provided for the metamizole sodium 1 H 2 O ID sachet.
  • Component 2 sustained release dose:
  • Titanium dioxide 2.45 mg
  • Dibutyl phthalate 5.00 mg These two types of granules or pellets, which were produced from components 1 and 2, are filled into sachets.
  • the active substance concentration of metamizole sodium 1 H 2 O per sachet is 1500 mg.
  • metamizole sodium 1 H 2 O -ID tab The following two components are provided for the metamizole sodium 1 H 2 O -ID tab.
  • Component 1 (initial dose powder):
  • Component 2 sustained release dose:
  • the sustained release granules or the sustained release pellets, which were produced from component 2, are pressed with component 1 into a tab.
  • the active substance concentration of metamizole sodium 1 H 2 O per sachet is 1500 mg.
  • metamizole sodium 1 H 2 O -ID tab The following two components are provided for the metamizole sodium 1 H 2 O -ID tab.
  • Component 1 (initial dose Garnulaf):
  • Component 2 sustained release dose:
  • This tablet core can also be covered with a film.
  • Metamizole sodium 1 H 2 O, methyl cellulose and lactose are mixed and passed through a sieve. This mixture is then moistened with a solution of PVP and water. Then it is granulated in a fluidized bed granulator. The granules are mixed with magnesium stearate and Aerosil and pressed into tabs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique solide à libération contrôlée à administrer par voie orale, qui contient comme principes actifs, une quantité efficace sur le plan thérapeutique de métamizol et/ou de ses sels pharmaceutiquement tolérables, lesdits principes actifs étant enrobés dans une matrice à libération contrôlée.
PCT/EP2000/003885 1999-05-04 2000-04-28 Composition pharmaceutique a liberation controlee contenant du metamizol WO2000066088A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45594/00A AU4559400A (en) 1999-05-04 2000-04-28 Controlled release pharmaceutical preparation containing metamizole

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999120415 DE19920415A1 (de) 1999-05-04 1999-05-04 Metamizol enthaltende, kontrolliert freisetzende pharmazeutische Zusammensetzung
DE19920415.2 1999-05-04

Publications (1)

Publication Number Publication Date
WO2000066088A1 true WO2000066088A1 (fr) 2000-11-09

Family

ID=7906884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003885 WO2000066088A1 (fr) 1999-05-04 2000-04-28 Composition pharmaceutique a liberation controlee contenant du metamizol

Country Status (3)

Country Link
AU (1) AU4559400A (fr)
DE (1) DE19920415A1 (fr)
WO (1) WO2000066088A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103610656A (zh) * 2013-12-05 2014-03-05 昆明振华制药厂有限公司 一种安乃近片的制备方法
WO2018087109A1 (fr) 2016-11-08 2018-05-17 Grünenthal GmbH Forme galénique multiparticulaire à libération de métamizole contrôlée

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
JP6786504B2 (ja) 2015-03-03 2020-11-18 キンドレッド バイオサイエンシズ インコーポレイテッド ウマにおける発熱の処置及び防止のための組成物及び方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0196119A (ja) * 1987-10-08 1989-04-14 Nitto Denko Corp 温度感応徐拡散性材
JPH06100602A (ja) * 1992-09-18 1994-04-12 Asahi Chem Ind Co Ltd 経口固形製剤およびその製造方法
US5500221A (en) * 1988-12-07 1996-03-19 Ss Pharmaceutical Co., Ltd. Sustained release suppository
EP0898961A1 (fr) * 1997-08-27 1999-03-03 Herta-Maria Dr. Sahlender Composition pharmaceutique pour améliorer la thérapie de la douleur aigüe, postoperatoire ou chronique
WO2000025750A1 (fr) * 1998-11-03 2000-05-11 Farmaceutici Formenti S.P.A. Compositions de metamizole a liberation prolongee

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0196119A (ja) * 1987-10-08 1989-04-14 Nitto Denko Corp 温度感応徐拡散性材
US5500221A (en) * 1988-12-07 1996-03-19 Ss Pharmaceutical Co., Ltd. Sustained release suppository
JPH06100602A (ja) * 1992-09-18 1994-04-12 Asahi Chem Ind Co Ltd 経口固形製剤およびその製造方法
EP0898961A1 (fr) * 1997-08-27 1999-03-03 Herta-Maria Dr. Sahlender Composition pharmaceutique pour améliorer la thérapie de la douleur aigüe, postoperatoire ou chronique
WO2000025750A1 (fr) * 1998-11-03 2000-05-11 Farmaceutici Formenti S.P.A. Compositions de metamizole a liberation prolongee

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; WATANABE, TETSUO ET AL: "Sustained - release materials useful for pharmaceuticals, pesticides, and foods", XP002147468, retrieved from STN Database accession no. 112:62645 CA *
DATABASE WPI Week 9419, Derwent World Patents Index; AN 1994-156663, XP002147469, "Oral preparation to mask unpleasant taste of drug" *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103610656A (zh) * 2013-12-05 2014-03-05 昆明振华制药厂有限公司 一种安乃近片的制备方法
CN103610656B (zh) * 2013-12-05 2016-02-03 昆明振华制药厂有限公司 一种安乃近片的制备方法
WO2018087109A1 (fr) 2016-11-08 2018-05-17 Grünenthal GmbH Forme galénique multiparticulaire à libération de métamizole contrôlée

Also Published As

Publication number Publication date
DE19920415A1 (de) 2000-11-09
AU4559400A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
DE60319252T2 (de) Formulierung von acetaminophen und tramadol mit verzögerter freisetzung
DE19940944B4 (de) Retardierte, orale, pharmazeutische Darreichungsformen
EP0069259B1 (fr) Forme retard de bromhexine et procédé de préparation
EP0068191B2 (fr) Formes orales du dipyridamole
DE69230112T2 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
EP1183015B1 (fr) Comprime a couches multiples pour l'administration d'une combinaison fixe de tramadol et de diclofenac
EP0917463B1 (fr) Formulations de tramadol a unites multiples
DE69629797T2 (de) Matrix zur gesteuerten freisetzung von arzneistoffen
EP0682945B1 (fr) Préparation orale à effet retard
EP1140031B1 (fr) Composition pharmaceutique a liberation controlee contenant comme principe actif du mesylate de tilidine
EP1113787B1 (fr) Preparations pharmaceutiques a liberation controlee en fonction de l'agitation et leur procede de production
EP1185253B1 (fr) Forme galenique orale servant a administrer une combinaison fixe de tramadol et de diclofenac
WO2000041681A2 (fr) FORMULATIONS DE MEDICAMENTS CONTENANT UN OPIOIDE ET UN α-AGONISTE
CH705273B1 (de) Pharmazeutische Zusammensetzung – umfassend Hydromorphon und Naloxon.
WO2006103551A1 (fr) Formulations d’oxycodone a liberation controlee
DE10209979A1 (de) Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
WO2000025756A2 (fr) Medicament pour le traitement topique de maladies intestinales inflammatoires
WO2000048577A1 (fr) Medicament destine au traitement ou a la prevention du cancer de l'intestin
WO2000066088A1 (fr) Composition pharmaceutique a liberation controlee contenant du metamizol
EP1374859B1 (fr) Composition pharmaceutique solide du chlorhydrate de tilidine
WO1994027596A1 (fr) Preparation pharmaceutique et son procede de fabrication
DE69817847T2 (de) In dosierinhalatoren verwendbare, stabilisierte zubereitungen
WO2018087109A1 (fr) Forme galénique multiparticulaire à libération de métamizole contrôlée
DE19845278A1 (de) Oral applizierbare Losigamon Retardtabletten

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载